Anesthesia and analgesia
-
Anesthesia and analgesia · May 1987
Comparative StudyBupivacaine disposition in mother, fetus, and neonate after spinal anesthesia for cesarean section.
Uptake of bupivacaine from the subarachnoid space and its placental transfer were measured in six patients undergoing elective cesarean section. Maternal plasma levels (59 +/- 32 ng/ml) were only about 5% of those found in a comparable previous study of epidural anesthesia. Mean plasma umbilical venous bupivacaine levels (20.2 +/- 21 ng/ml) were 7% of those found after epidural anesthesia. ⋯ Neonatal urine had measurable levels of both bupivacaine and its inactive metabolite, 2,6-pipecolylxylidine (PPX), for at least 36 hr after delivery. The results demonstrate that bupivacaine crosses the placenta and reaches the fetus, but in very low amounts. This transplacental passage occurs despite injection of only small doses of a very highly protein bound drug into the subarachnoid space.
-
Anesthesia and analgesia · May 1987
Comparative StudyPlasma concentrations of epidural bupivacaine in mother and newborn: 0.125% versus 0.375%.
Central venous plasma concentrations of bupivacaine were determined in two groups of 15 parturients each who were given epidural analgesia for labor and vaginal delivery. One group received 10 ml of 0.125% bupivacaine plus epinephrine 1:800,000, the other group received 7 ml of 0.375% bupivacaine plus epinephrine 1:800,000. Plasma concentrations of bupivacaine in the umbilical venous (UV) and the umbilical arterial (UA) blood of their babies were also determined. ⋯ The measured plasma concentrations speak in favor of the less concentrated solution of bupivacaine in epidural analgesia for obstetrics. Seven milliliters of bupivacaine 0.375% is suitable for epidural analgesia in obstetrics but a low concentration-low dose technique, using 10 ml of bupivacaine 0.125% plus epinephrine 1:800,000 is safer. It provides good analgesia with minimal or no motor block and is associated with low maternal and neonatal plasma concentrations of bupivacaine, well below toxic levels and, to our knowledge, lower than in any other study.
-
Anesthesia and analgesia · Apr 1987
Randomized Controlled Trial Clinical TrialA randomized prospective controlled study of the metabolism and hepatotoxicity of halothane in humans.
In a randomized prospective controlled study in humans, the metabolism and hepatic effects of a single administration of halothane were compared with enflurane and meperidine. Pre- and postoperative antipyrine pharmacokinetics, intraoperative indocyanine green clearance, liver histology, and postoperative liver function tests were determined in 24 patients undergoing abdominal surgery who were randomly allocated to receive either halothane (0.5%, group I), enflurane (0.8%, group II), or meperidine (group III) as a supplement to a common basal anesthetic regimen consisting of thiopental, nitrous oxide/oxygen/muscle relaxant. In addition, end-tidal concentrations of the volatile reductive metabolites of halothane, chlorodifluoroethylene (CDF), and chlorotrifluoroethane (CTF) were determined in group I patients and serum and urinary inorganic fluoride were determined in both group I and II patients. ⋯ There were no significant differences in liver cell morphology (P greater than 0.5) in biopsies taken at the end of stage IV compared with biopsies at the end of stage III, from groups I and II. The results of this study show that reductive metabolism of halothane occurs routinely in patients undergoing halothane anesthesia under conditions of normoxia. This may be the cause of the changes in antipyrine clearance after halothane anesthesia.
-
Anesthesia and analgesia · Apr 1987
Blood levels of mepivacaine during continuous epidural anesthesia.
Venous blood concentrations of mepivacaine were measured in 30 patients during 5 hr of surgical anesthesia following either multiple epidural injections of mepivacaine with or without epinephrine or continuous epidural infusion of mepivacaine with epinephrine. Patients were divided into three groups: group 1 initially received 10 or 15 ml followed by 10 ml of 2% plain mepivacaine at 1-hr intervals; group 2 received 10 or 15 ml followed by 10 ml of epinephrine-containing 2% mepivacaine at 1-hr intervals; group 3 received 10 or 15 ml followed by a constant infusion of 10 ml/hr of epinephrine-containing 2% mepivacaine. ⋯ The mean blood concentration of mepivacaine in group 3 remained significantly lower than the concentrations in groups 1 and 2 from 3.5 to 5 hr. These results demonstrate that the blood concentrations of mepivacaine are not reduced by the addition of epinephrine to mepivacaine solutions when intermittent epidural injections are repeated more than four times at 1-hr intervals, but that blood mepivacaine levels are reduced below levels seen with intermittent injections by the continuous epidural infusion of epinephrine-containing mepivacaine.